

Table S3. Comparison of AP characteristics of the developed model (vCa) and the two extended variants (vCaNass and vCaNasslk) to experiments

Parameter	vCA	vCaNass	vCaNasslk	Experimental value [ref]
V_{diast} (mV)	-77.0	-76.0	-75.3	-79.9 ± 1.3 [1]; T = 36°C -75 ± 1 [2]; T = 35°C -68 ± 8 [3]; T = 37°C
V_{syst} (mV)	41.7	41.6	41.7	35 ± 2.8 [1]; T = 36°C 53 ± 2 [4]; T = 37°C
V_{ampl} (mV)	118.8	117.7	117.0	98 ± 5 [5]; T = 36°C 118.33 ± 3.00 [6]; T = 36°C 130 ± 2 [4]; T = 37°C
dV/dt_{max} (mV/ms)	170	169	168	167 ± 26 [5]; T = 36°C 231.9 ± 13.6 [6]; T = 36°C 172 ± 60 [7]; T = 31°C
APD_{30} (ms)	10.6	10.8	10.8	13 ± 16 [7]; T = 31°C 13.9 ± 3.7 [8]; T = 23°C; 0.5 Hz
APD_{50} (ms)	21.0	20.8	20.8	7.65 ± 1.12 [1]; T = 36°C 62 ± 91 [7]; T = 31°C 25 ± 3 [3]; T = 37°C
APD_{75} (ms)	145.4	148.4	136.0	141 ± 12 [9]; T = 37°C
APD_{90} (ms)	239.4	244.4	246.8	204 ± 11 [10]; T = 36°C 237 ± 18 [9]; T = 37°C 255 ± 45 [11]; T = 35°C

REFERENCES

1. Wang YG, Xu HY, Kumar R, Tipparaju SM, Wagner MB, et al. (2003) Differences in transient outward current properties between neonatal and adult human atrial myocytes. *Journal of Molecular and Cellular Cardiology* 35: 1083-1092.
2. Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, et al. (2004) Role of I-Kur in controlling action potential shape and contractility in the human atrium - Influence of chronic atrial fibrillation. *Circulation* 110: 2299-2306.
3. Dobrev D, Graf E, Wettwer E, Himmel HM, Hala O, et al. (2001) Molecular Basis of Downregulation of G-Protein-Coupled Inward Rectifying K⁺ Current (I_{K,ACh}) in Chronic Human Atrial Fibrillation: Decrease in GIRK4 mRNA Correlates With

Reduced $I_{K,ACh}$ and Muscarinic Receptor-Mediated Shortening of Action Potentials. *Circulation* 104: 2551-2557.

4. Workman AJ, Kane KA, Russell JA, Norrie J, Rankin AC (2003) Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. *Cardiovasc Res* 58: 518-525.
5. Wang Z, Pelletier L, Talajic M, Nattel S (1990) Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. *Circulation* 82: 274-283.
6. Lagrutta A, Wang JX, Fermini B, Salata JJ (2006) Novel, potent inhibitors of human Kv1.5 K⁺ channels and ultrarapidly activating delayed rectifier potassium current. *Journal of Pharmacology and Experimental Therapeutics* 317: 1054-1063.
7. Dawodu AA, Monti F, Iwashiro K, Schiariti M, Chiavarelli R, et al. (1996) The shape of human atrial action potential accounts for different frequency-related changes in vitro. *Int J Cardiol* 54: 237-249.
8. Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, et al. CaMKII-Dependent Diastolic SR Ca²⁺ Leak and Elevated Diastolic Ca²⁺ Levels in Right Atrial Myocardium of Patients With Atrial Fibrillation. *Circ Res* 106: 1134-1144.
9. Pau D, Workman AJ, Kane KA, Rankin AC (2005) Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. *J Pharmacol Exp Ther* 313: 146-153.
10. Dobrev D, Ravens U (2003) Remodeling of cardiomyocyte ion channels in human atrial fibrillation. *Basic Res Cardiol* 98: 137-148.
11. Bosch RF, Zeng XR, Grammer JB, Popovic K, Mewis C, et al. (1999) Ionic mechanisms of electrical remodeling in human atrial fibrillation. *Cardiovasc Res* 44: 121-131.